Cardinal Health, Inc. (VIE:CAHE)
Austria · Delayed Price · Currency is EUR | Market Cap | 50.85B +52.0% |
| Revenue (ttm) | 222.54B +14.2% |
| Net Income | 1.50B +9.8% |
| EPS | 6.49 +12.1% |
| Shares Out | n/a |
| PE Ratio | 33.99 |
| Forward PE | 19.36 |
| Dividend | 1.79 (0.81%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | n/a |
| Open | 221.40 |
| Previous Close | 222.60 |
| Day's Range | 220.70 - 222.60 |
| 52-Week Range | 203.60 - 231.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. T... [Read more]
Financial Performance
In fiscal year 2026, Cardinal Health's revenue was $254.25 billion, an increase of 14.23% compared to the previous year's $222.58 billion. Earnings were $1.71 billion, an increase of 9.80%.
Financial numbers in USD Financial StatementsNews
Cardinal Health, McKesson awarded $2.7B and $741.5M DLA contracts respectively
Cardinal Health (CAH) and McKesson (MCK) have each been awarded fixed-price, indefinite-delivery/indefinite-quantity contracts worth $2.7B and $741.5M respectively under a solicitation for the Medical...
Cardinal Health price target raised to $280 from $250 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $280 from $250 and keeps an Outperform rating on the shares. The firm adjusted targets in the drug distributor…
Cardinal Health price target raised to $295 from $280 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health (CAH) to $295 from $280 and keeps a Buy rating on the shares.
CVS extensions ‘a clearing event’ for McKesson, Cardinal Health, says BofA
BofA reiterates Buy ratings on McKesson (MCK) and Cardinal Health (CAH) after both companies announced deals to extend distribution agreements with CVS Health (CVS). The extension of the CVS contracts...
Cardinal Health enters LOI to extend distribution agreements with CVS Health
Cardinal Health (CAH) has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health (CVS) through June 30, 2032, reflecting the continuation of Cardinal…
Cardinal Health reaffirms FY27 non-GAAP EPS view $12.40-$12.60, consensus $12.57
In connection with the renewal, Cardinal Health (CAH) has reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, and its long-term non-GAAP…
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health...
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2027 on November 5, prior to the opening of trading on the N...
Cardinal Health Proxy statement: Proxy filing
Cardinal Health filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Cardinal Health Proxy statement: Proxy filing
Cardinal Health filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Cardinal Health Transcript: 2026 Global Healthcare Conference
All five segments posted double-digit earnings growth in 2026, led by specialty and supported by successful acquisitions. The business mix is shifting toward higher-margin areas, with strong cash flow and a robust acquisition pipeline, though future growth is expected to normalize.
Cardinal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Fiscal 2027 guidance projects 13%-15% EPS growth, driven by strong performance across all segments and continued investment in specialty, pharma, and at-home solutions. Strategic customer relationships, diversified revenue streams, and proactive policy management support long-term growth and resilience.
Cardinal Health Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong FY 2026 results were driven by specialty and generics, with FY 2027 guidance above long-term targets. Growth is supported by acquisitions, robust specialty and nuclear businesses, and disciplined capital allocation, while AI and cost optimization remain key priorities.
Cardinal Health initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Cardinal Health (CAH) with an Outperform rating and $276 price target The firm views the vertical integration of the company’s “higher-growth and higher-margin” servi...
Cardinal Health price target raised to $274 from $251 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Cardinal Health (CAH) to $274 from $251 and keeps an Outperform rating on the shares.
Cardinal Health price target raised to $280 from $265 at Citi
Citi raised the firm’s price target on Cardinal Health (CAH) to $280 from $265 and keeps a Buy rating on the shares. The firm views the company’s fiscal Q4 report…
Cardinal Health price target raised to $277 from $245 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cardinal Health (CAH) to $277 from $245 and keeps an Overweight rating on the shares. The firm is raising…
Cardinal Health price target raised to $250 from $240 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $250 from $240 and keeps an Outperform rating on the shares. The firm says management reinforced its positive preview…
Cardinal Health price target raised to $280 from $274 at UBS
UBS raised the firm’s price target on Cardinal Health (CAH) to $280 from $274 and keeps a Buy rating on the shares. Momentum is continuing into FY27, but the focus…
Cardinal Health price target raised to $270 from $265 at Evercore ISI
Evercore ISI raised the firm’s price target on Cardinal Health (CAH) to $270 from $265 and keeps an Outperform rating on the shares.
Cardinal Health price target raised to $265 from $255 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $265 from $255 and keeps an Overweight rating on the shares.
Cardinal Health price target raised to $275 from $258 at Barclays
Barclays raised the firm’s price target on Cardinal Health (CAH) to $275 from $258 and keeps an Overweight rating on the shares. The firm says Cardinal Health offered a “reasonably…
Cardinal Health price target raised to $260 from $215 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Cardinal Health (CAH) to $260 from $215 and keeps a Neutral rating on the shares post the fiscal Q4 earnings…
Cardinal Health Earnings Call Transcript: Q4 2026
Q4 and fiscal 2026 saw strong revenue, profit, and cash flow growth, led by Pharmaceutical and Specialty Solutions and other growth businesses. Fiscal 2027 guidance calls for double-digit EPS and profit growth, continued investment, and robust capital returns, with risks from tariffs, input costs, and regulatory changes.